

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. – 19. (Canceled)

20. (Currently Amended) A method for reducing the risk of relapse in a subject at risk of relapse of a cancer, the cells of which express NY-ESO-1, comprising administering to said subject an amount of a composition containing full length NY-ESO-1 protein and a saponin based adjuvant in a ratio of about 1:1 by weight, sufficient to induce an antibody response to NY-ESO-1 in said subject and reduce the risk of relapse.

21. (Previously Presented) The method of claim 20, wherein the amount of said composition is sufficient to induce both a CD4<sup>+</sup> and a CD8<sup>+</sup>T cell response.

22. (Original) The method of claim 20, comprising administering said composition intramuscularly or subcutaneously.

23. – 24. (Canceled)

25. (Original) The method of claim 20, comprising administering equal amounts of NY-ESO-1 and saponin based adjuvant to said subject.

26. (Original) The method of claim 20, comprising administering from about 10 to about 500µg of NY-ESO-1 protein to subject.

27. – 33. (Canceled)

34. (Previously Presented) The method of claim 20, wherein the saponin based adjuvant comprises the full length NY-ESO-1 protein in association with a saponin and a sterol via hydrophobic interactions.

35. (Previously Presented) The method of claim 20, wherein the full length NY-ESO-1 protein is not associated with a saponin and a sterol in the saponin based adjuvant via hydrophobic interactions.

36. (Previously Presented) The method of claim 20, comprising administering said composition intradermally.

37. (Previously Presented) The method of claim 26, comprising administering about 100  $\mu$ g of NY-ESO-1 protein to said subject.